generic drugs

Perrigo Reports Record Revenue; Acquisition Charges Ding Profits

The generic drug and store brand health products maker Perrigo Co. (Nasdaq: PRGO) Wednesday reported record revenue of $919.8 million in the third fiscal quarer ended March 30, up from $778 million a year earlier.

WWJ Newsradio 950–2013/05/08

Perrigo Announces Commercial Launch Of Betamethasone Foam

Perrigo Co. Tuesday announced that it has begun commercial shipments of betamethasone valerate foam 0.12%, the generic equivalent of Luxiq Foam, consistent with the date certain launch settlement previously announced.

WWJ Newsradio 950–2013/01/15

Perrigo Announces Launch of Authorized Generic Version of Acetadote, Plus Infant Formulas

Allegan-based Perrigo Co. announced that it has made initial shipments distributing Cumberland Pharmaceuticals Inc.’s authorized generic form of Acetadote (acetylcysteine) injection, and that it had received FDA clearance to manufacture new infant formula products.

WWJ Newsradio 950–2013/01/07

Perrigo Confirms Settlement Of Generic Acetadote Injection Patent Lawsuit

The generic drug and over-the-counter health product manufacturer Perrigo Co. (Nasdaq: PRGO) announced that it has agreed to settle its Hatch-Waxman litigation relating to Acetadote (acetylcysteine) injection brought by Cumberland Pharmaceuticals Inc.

WWJ Newsradio 950–2012/11/13

Perrigo Reports Record First Quarter Revenue, Earnings

The Allegan-based generic drug and health products manufacturer Perrigo Co. (Nasdaq: PRGO) Wednesday reported net income of $106 million or $1.12 a share in the first fiscal quarter ended Sept. 29, up from $70.5 or 75 cents a share in the same quarter a year earlier.

WWJ Newsradio 950–2012/11/07

Perrigo Sales, Profits Both Jump 15 Percent For Fiscal Year

The generic drug and store-brand health and beauty products maker Perrigo Co. (Nasdaq: PRGO) Thursday reported net income fo $393 million or $4.18 a share in its fiscal year ended June 30, up 15 percent from $340.6 million or $3.64 a share in the prior fiscal year.

WWJ Newsradio 950–2012/08/16

Perrigo Launches Generic Mucinex

Perrigo Co. (Nasdaq: PRGO) announced that it has initiated shipments of its Guaifenesin Extended-Release Tablets, 600mg, a generic version of Mucinex 600mg tablets.

WWJ Newsradio 950–2012/04/15

Perrigo Launches Store Brand Version Of Claritin-D

Perrigo Co. announced that it has begun shipping Loratadine-D 12 hour extended release tablets, the store brand equivalent to Schering-Plough’s Claritin-D 12 hour extended release tablets.

WWJ Newsradio 950–2012/02/14

Perrigo Company Announces Quarterly Dividend

Perrigo Co. Thursday announced that its Board of Directors declared a quarterly dividend of 8 cents a share.

WWJ Newsradio 950–2012/02/02

Perrigo Acquires Assets of CanAm Care for $36 Million

Perrigo Co. (Nasdaq: PRGO) announced that it has signed a definitive agreement to acquire substantially all of the assets of CanAm Care, a privately-held, Alpharetta, Ga.-based distributor of diabetes care products for approximately $36 million in cash.

WWJ Newsradio 950–2012/01/10

Listen Live!